Chemplast Sanmar denies acquisition of Symed Labs
Chemplast Sanmar Limited, a listed pharmaceutical and specialty chemicals manufacturer, formally denied via NSE intimation that it had entered into any definitive agreement to acquire Symed Labs Limited. The denial was filed under Regulation 30(11) of the SEBI Listing Obligations and Disclosure Requirements (LODR), 2015, which requires listed companies to immediately correct or clarify any material news that may be misleading. No transaction value, consideration structure, or conditions were disclosed, as the company categorically denied the transaction.
Why it mattersThe Regulation 30(11) denial establishes that no material agreement existed as at the filing date; counsel advising on any subsequent Chemplast–Symed transaction must establish independent due diligence and document that any future agreement is arm's length and material-event-gated, given the prior market denial.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives (Corporate Announcements) · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026